Quality of life in adults with brain tumors: Current knowledge and future directions

Department of Neurological Surgery, University of California, San Francisco, CA 94143-0350, USA.
Neuro-Oncology (Impact Factor: 5.56). 12/2008; 11(3):330-9. DOI: 10.1215/15228517-2008-093
Source: PubMed


Quality of life is an important area of clinical neurooncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. This review of quality-of-life studies in the brain tumor population aims to summarize what is currently known about quality of life in patients with both low-grade and high-grade tumors and suggest how we may use this knowledge to direct future research. To date, reports on quality of life have been primarily qualitative and focused on specific symptoms such as fatigue, sleep disorders, and cognitive dysfunction, as well as some symptom clusters. However, the increasing interest in exploring quality of life as a primary end point for cancer therapy has established a need for prospective, controlled studies to assess baseline and serial quality-of-life parameters in brain tumor patients in order to plan and evaluate appropriate and timely interventions for their symptoms.

Download full-text


Available from: Susan M Chang,
  • Source
    • "Aunque la información sobre la calidad de vida en pacientes con gliomas es dispar, en función de los objetivos de cada investigación, diferentes autores (Gilbert, Armstrong y Meyers, 2000; Gustafsson, Eduardsson y Ahlstrom, 2006; Hanh et al., 2003; Heimans y Taphoorn , 2002; Liu, Page, Solheim, Fox y Chang, 2009; Taphoorn, Sizoo y Bottomley, 2010; Weitzner y Meyers, 1997) han indicado que la dimensión psicológica parece ser la más afectada, independientemente de la fase de enfermedad o de otras variables de la misma. En este sentido, Bosma et al. (2009) y Liu et al. (2009) indican que en pacientes con gliomas no se producía una mejoría en la calidad de vida global hasta que no se reestablecía el bienestar emocional doce meses después del diagnóstico. En la misma línea de trabajo, diferentes autores han observado correlaciones significativas entre la calidad de vida y algunas variables psicológicas (funciones cognitivas y/o síntomas clínicos de ansiedad y depresión), que no se repetían con otras medidas funcionales o con el bienestar físico para pacientes con gliomas ni en otras poblaciones examinadas (pacientes con enfermedades neurológicas crónicas o individuos sanos). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical symptoms of anxiety and depression as well as cognitive impairment determine the quality of life of patients with brain tumors (Liu, Page, Solheim, Fox, & Chang, 2009). The aim of this paper is to analyze the quality of life and its relationship to psychological variables in individuals diagnosed with glioma six months earlier. The sample consisted of 28 patients (58.6% male) with a mean age of 54.38 and 89.2% of them receiving adjuvant therapy (chemotherapy). All subjects were administered a neuropsychological battery assessing quaility of life, anxiety and depression, attention, memory, language, visuoconstructive skills, visual organization, language, and executive functions. These patients have a worse quality of life in certain dimensions (physical, functional, family) and overall perception of well-being. All areas of quality of life are associated with mood and the presence of clinical manifestations of depression accounts for a lower quality of life. On the other hand, improved cognitive performance in object recognition processes, memory, and planning indicates a higher overall quality of life of these patients.
    Clínica y Salud 03/2015; 1(1). DOI:10.1016/j.clysa.2014.07.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Perceived quality of life (QOL) was evaluated in a group of 50 patients with primary brain tumors. Participants completed two QOL measures and a demographic profile. Age was found not to be an important factor in differentiating QOL in these patients. All areas of QOL were found to be affected adversely by one or more of five factors: being female, being divorced, having bilateral tumor involvement, having received chemotherapy, and having a poor performance status. Pearson product-moment correlations conducted on the subscale and total scores of the two QOL instruments revealed that the two scales measure different QOL aspects and overlap in only a few areas. This may be related to the different measurement paradigms that these two instruments represent. This study is one of the first to evaluate the multidimensional aspects of QOL in patients with primary brain tumors, an understudied group. A prospective study of QOL in this group, already underway at the authors' institution, is needed to evaluate comprehensively the effect of different treatments and interventions on the QOL functioning of primary brain tumor patients. Additionally, this study shows that the choice of QOL instruments is very important and needs to be driven by the research question.
    Journal of Neurosurgery 02/1996; 84(1):29-34. DOI:10.3171/jns.1996.84.1.0029 · 3.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study was undertaken to evaluate cardiorespiratory fitness, skeletal muscle function, and body composition of patients with newly diagnosed and untreated, postsurgical primary malignant glioma. By using a cross-sectional design, patients with clinically stable (10 +/- 7 days postsurgery) high-grade glioma (HGG; n = 25) or low-grade glioma (LGG; n = 10) were studied. Participants performed a cardiopulmonary exercise test (CPET) with expired gas analysis to assess cardiorespiratory fitness (peak oxygen consumption, VO2peak). Other physiological outcomes included skeletal muscle cross-sectional area (CSA; magnetic resonance imaging), isokinetic muscle strength (isokinetic dynamometer), and body composition (air displacement plethysmography). Quality of life was assessed with the Functional Assessment of Cancer Therapy-Brain scale. CPET was a feasible and safe procedure to assess VO2peak, with no serious adverse events. VO2peak indexed to total body weight and lean body mass (LBM) for both groups was 13.0 mL x weight x min(-1) and 19 mL x LBM x min(-1), the equivalent to 59% and 38% below age- and sex-predicted normative values, respectively. Skeletal muscle strength and mid-thigh CSA were lower in HGG relative to LGG patients (83 vs 125 Nm, P = .025; 94 vs 119 cm2, P = .171, respectively). Skeletal muscle isokinetic strength, CSA, and body composition outcomes predicted VO2peak (r = -0.59 to 0.68, P < .05). Postsurgical glioma patients have markedly reduced cardiorespiratory fitness, isokinetic strength, and CSA. Prospective studies are now required to determine whether such abnormalities influence treatment toxicity and clinical outcome as well as to test the effect of appropriately selected interventions to prevent and/or mitigate dysfunction.
    Cancer 02/2010; 116(3):695-704. DOI:10.1002/cncr.24808 · 4.89 Impact Factor
Show more